Advertisement
Canada markets closed
  • S&P/TSX

    21,947.41
    +124.19 (+0.57%)
     
  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     
  • DOW

    38,675.68
    +450.02 (+1.18%)
     
  • CAD/USD

    0.7308
    -0.0006 (-0.08%)
     
  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     
  • Bitcoin CAD

    87,571.67
    +2,137.72 (+2.50%)
     
  • CMC Crypto 200

    1,359.39
    +82.41 (+6.45%)
     
  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     
  • RUSSELL 2000

    2,035.72
    +19.61 (+0.97%)
     
  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     
  • NASDAQ

    16,156.33
    +315.37 (+1.99%)
     
  • VOLATILITY

    13.49
    -1.19 (-8.11%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • CAD/EUR

    0.6787
    -0.0030 (-0.44%)
     

Today's Free Reports Concordia International ProMetic Life Sciences Oncolytics Biotech and Aurinia Pharma

LONDON, UK / ACCESSWIRE / July 18, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges’ equities from the Biotechnology industry: Concordia International, ProMetic Life Sciences, Oncolytics Biotech, and Aurinia Pharmaceuticals. Access our complimentary up-to-the-minute research reports by becoming an online member now:

www.active-investors.com/registration-sg

The S&P/TSX Composite Index progressed 24.51 points, or 0.15%, to close Tuesday’s trading session at 16,519.24. The TSX Venture Exchange shaved off 2.52 points, or 0.35%, to finish at 713.11.

Moreover, the Healthcare index was down by 1.26%, closing at 93.40.

ADVERTISEMENT

Today’s stocks of interest consist of: Concordia International Corporation (TSX: CXR), ProMetic Life Sciences Inc. (TSX: PLI), Oncolytics Biotech Inc. (TSX: ONC), and Aurinia Pharmaceuticals Inc. (TSX: AUP). Click the link below to view a sample of the free research report that will be available to you as a member of Active-Investors:

www.active-investors.com/registration-sg

Concordia International Corp.

Oakville, Canada headquartered Concordia International Corp.'s stock finished Tuesday's session flat at $0.26 with a total volume of 18,063 shares traded. Over the last month and the previous three months, Concordia International's shares have advanced 1.62% and 2.81%, respectively. Furthermore, the stock has gained 5.58% in the past year. Shares of the Company, which through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products, are trading below its 50-day and 200-day moving averages. Concordia International’s 200-day moving average of $0.60 is above its 50-day moving average of $0.28. View the research report on CXR.TO at:

www.active-investors.com/registration-sg/?symbol=CXR

ProMetic Life Sciences Inc.

On Tuesday, shares in Laval, Canada headquartered ProMetic Life Sciences Inc. recorded a trading volume of 1.18 million shares. The stock ended the day 9.59% lower at $0.66. ProMetic Life Sciences’ stock has advanced 4.76% in the last month. Shares of the Company, which develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products, are trading below its 50-day and 200-day moving averages. The stock’s 200-day moving average of $1.08 is above its 50-day moving average of $0.67. Get the free report on PLI.TO at:

www.active-investors.com/registration-sg/?symbol=PLI

Oncolytics Biotech Inc.

On Tuesday, shares in Calgary, Canada headquartered Oncolytics Biotech Inc. ended the session 0.28% higher at $7.12 with a total volume of 9,000 shares traded. Oncolytics Biotech's shares have surged 8.64% in the last three months and 41.06% in the previous year. Shares of the Company, which focuses on the discovery and development of pharmaceutical products for the treatment of cancer, are trading below its 50-day and 200-day moving averages. Furthermore, the stock’s 50-day moving average of $8.48 is greater than its 200-day moving average of $7.41. Access the most recent report coverage on ONC.TO at:

www.active-investors.com/registration-sg/?symbol=ONC

Aurinia Pharmaceuticals Inc.

Victoria, Canada headquartered Aurinia Pharmaceuticals Inc.'s stock closed the day 0.80% lower at $7.47. The stock recorded a trading volume of 10,050 shares. Aurinia Pharma's shares have gained 9.21% in the past three months. Shares of the Company, which engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the US, China, and Switzerland, are trading above their 200-day moving average. Moreover, the stock’s 50-day moving average of $7.52 is greater than its 200-day moving average of $7.03. Today’s complimentary report on AUP.TO can be accessed at:

www.active-investors.com/registration-sg/?symbol=AUP

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

SOURCE: Active-Investors